PHARMACOVIGILANCE BASED DRUG SAFTY PROFILE OF CLONIDINE: CASE STUDIES FROM YEAR 2000 TO 2025
Clonidine; Alpha-2 adrenergic agonist; Adverse drug reactions; Rebound hypertension; Toxicity management
Clonidine acts within the central nervous system as an α₂-adrenergic receptor agonist, where it suppresses sympathetic nerve activity, resulting in decreased heart rate and blood pressure. Initially approved as an antihypertensive agent in 1974, its clinical applications have expanded to include attention-deficit hyperactivity disorder (ADHD), Tourette syndrome, cancer pain, menopausal vasomotor symptoms, and management of substance withdrawal. It has diverse therapeutic uses across pediatric, adult, and geriatric populations, understanding its safety profile is essential.
The pharmacological effects of clonidine on the cardiovascular and central nervous systems account for both its therapeutic benefits and its adverse drug reactions. Typical side effects reported with clonidine therapy include drowsiness, light-headedness, and dryness of the mouth, constipation, fatigue, hypotension. More serious reactions such as marked bradycardia, atrioventricular block, syncope, severe hypotension, respiratory depression, and rebound hypertension following abrupt discontinuation have been reported. Toxicity primarily manifests as central nervous system depression, bradycardia, and hypotension due to excessive central alpha-2 receptor stimulation and suppression of norepinephrine release. Pediatric patients are particularly vulnerable to pronounced sedation and cardiovascular instability even at relatively low doses.
Management of clonidine toxicity is largely supportive and depends on clinical severity. Treatment strategies include airway protection, mechanical ventilation, when necessary, intravenous fluid resuscitation, atropine for symptomatic bradycardia, and inotropic support for refractory hypotension. Naloxone has been used in selected cases with variable outcomes. Abrupt withdrawal requires cautious reintroduction and gradual tapering to prevent hypertensive crises.
This review summarizes the pharmacological mechanisms, therapeutic indications, adverse drug reactions, toxicity patterns reported between 2000 and 2025, and current management strategies. A comprehensive evaluation of real-world safety data highlights the importance of pharmacovigilance in promoting rational prescribing and minimizing preventable harm associated with clonidine therapy.
Registration ID: IJVRA_701954 Published ID: IJVRA2603458
"PHARMACOVIGILANCE BASED DRUG SAFTY PROFILE OF CLONIDINE: CASE STUDIES FROM YEAR 2000 TO 2025", IJVRA - International Journal of Versatile Research and Analysis (www.IJVRA.org), ISSN:2984-8903, Vol.4, Issue 3, page no.500-510, March-2026, Available :https://ijpub.org/ijvra/papers/IJVRA2603458.pdf
Paper Reg. ID: IJVRA_701954
Published Paper Id: IJVRA2603458
Research Area: Pharmacy All
Country: Kolhapur, Maharashtra, India
ISSN: 2984-8903 | IMPACT FACTOR: 9.12 Calculated By Google Scholar | ESTD YEAR: 2023
An International UGC CARE JOURNAL PUBLICATION Low Cost (₹599), Scholarly Open Access, Peer-Reviewed, Refereed Journal Impact Factor 9.12 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage, Crossref DOI Member Journal Indexing in All Major Database & Metadata, Citation Generator
Publisher: IJVRA (IJ Publication) Janvi Wave
© 2026 - Authors hold the copyright of this article. This work is licensed under a Creative Commons Attribution 4.0 International License and The Open Definition.
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0). 🛡️ Disclaimer:
The content, data, and findings in this article are based on the authors’ research and have been peer-reviewed for academic purposes only. Readers are advised to verify all information before practical or commercial use. The journal and its editorial board are not liable for any errors, losses, or consequences arising from its use.
: Click Here to Get
About Hard Copy and Transparent Peer Review Report
